Financial crisis looms for New Zealand laboratories
This article was originally published in Clinica
Clinical labs in New Zealand are running into serious financial difficulties, warns the Association of Community Laboratories. Many labs are likely to become non-viable within the next two years unless new regional health authority funding is forthcoming, since no compensation for the rising cost of diagnostic testing has been paid by the government since 1993.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.